Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management

被引：0

作者：

Gilbert, T. M. ^{[1
,2
]}

Randle, L. ^{[2
]}

Quinn, M. ^{[1
]}

Mcgreevy, O. ^{[2
]}

O'leary, L. ^{[1
]}

Young, R. ^{[1
,2
]}

Diaz-Neito, R. ^{[1
]}

Jones, R. P. ^{[1
,2
]}

Greenhalf, B. ^{[4
]}

Goldring, C. ^{[2
]}

Fenwick, S. ^{[1
]}

Malik, H. ^{[1
]}

Palmer, D. H. ^{[3
,4
]}

机构：

[1] Liverpool Univ Hosp NHS FT, Hepatobiliary Surg, Liverpool, England

[2] Univ Liverpool, Inst Syst Integrat & Mol Biol, Dept Pharmacol & Therapeut, Liverpool, England

[3] Clatterbridge Canc Ctr, Liverpool, England

[4] Univ Liverpool, Liverpool Expt Canc Med Ctr, Liverpool, England

来源：

EJSO | 2025年 / 51卷 / 02期

基金：

英国国家替代、减少和改良动物研究中心;

关键词：

Cholangiocarcinoma; Molecular biology; Targeted therapy; Patient treatment; BILIARY-TRACT CANCER; INTRAHEPATIC CHOLANGIOCARCINOMA; OPEN-LABEL; MULTICENTER; GEMCITABINE; MUTATIONS; CISPLATIN; CHEMORESISTANCE; SURVIVAL; GROWTH;

D O I：

10.1016/j.ejso.2024.108352

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cholangiocarcinoma (CCA) remains a devastating malignancy and a significant challenge to treat. The majority of CCA patients are diagnosed at an advanced stage, making the disease incurable in most cases. The advent of high-throughput genetic sequencing has significantly improved our understanding of the molecular biology underpinning cancer. The identification of 'druggable' genetic aberrations and the development of novel targeted therapies against them is opening up new treatment strategies. Currently, 3 targeted therapies are approved for use in CCA; Ivosidenib in patients with IDH1 mutations and Infigratinib/Pemigatinib in those with FGFR2 fusions. As our understanding of the biology underpinning CCA continues to improve it is highly likely that additional targeted therapies will become available in the near future. This is important, as it is thought up to 40 % of CCA patients harbour a potentially actionable mutation. In this review we provide an overview of the molecular pathogenesis of CCA and highlight currently available and potential future targeted treatments.

引用

页数：8

共 94 条

[1] Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202. [J].

Abou-Alfa, Ghassan K. ;

Sahai, Vaibhav ;

Hollebecque, Antoine ;

Vaccaro, Gina M. ;

Melisi, Davide ;

Al-Rajabi, Raed Moh'd Taiseer ;

Paulson, Andrew Scott ;

Borad, Mitesh J. ;

Gallinson, David H. ;

Murphy, Adrian Gerard ;

Oh, Do-Youn ;

Dotan, Efrat ;

Catenacci, Daniel ;

Van Cutsem, Eric ;

Lihou, Christine Francis ;

Zhen, Huiling ;

Feliz, Luis ;

Vogel, Arndt .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[2] Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study [J].

Abou-Alfa, Ghassan K. ;

Macarulla, Teresa ;

Javle, Milind M. ;

Kelley, Robin K. ;

Lubner, Sam J. ;

Adeva, Jorge ;

Cleary, James M. ;

Catenacci, Daniel V. ;

Borad, Mitesh J. ;

Bridgewater, John ;

Harris, William P. ;

Murphy, Adrian G. ;

Oh, Do-Youn ;

Whisenant, Jonathan ;

Lowery, Maeve A. ;

Goyal, Lipika ;

Shroff, Rachna T. ;

El-Khoueiry, Anthony B. ;

Fan, Bin ;

Wu, Bin ;

Chamberlain, Christina X. ;

Jiang, Liewen ;

Gliser, Camelia ;

Pandya, Shuchi S. ;

Valle, Juan W. ;

Zhu, Andrew X. .

LANCET ONCOLOGY, 2020, 21 (06) :796-807

[3] Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [J].

Abou-Alfa, Ghassan K. ;

Sahai, Vaibhav ;

Hollebecque, Antoine ;

Vaccaro, Gina ;

Melisi, Davide ;

Al-Rajabi, Raed ;

Paulson, Andrew S. ;

Borad, Mitesh J. ;

Gallinson, David ;

Murphy, Adrian G. ;

Oh, Do-Youn ;

Dotan, Efrat ;

Catenacci, Daniel, V ;

Van Cutsem, Eric ;

Ji, Tao ;

Lihou, Christine F. ;

Zhen, Huiling ;

Feliz, Luis ;

Vogel, Arndt .

LANCET ONCOLOGY, 2020, 21 (05) :671-684

[4] Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged [J].

Alabraba, E. ;

Joshi, H. ;

Bird, N. ;

Griffin, R. ;

Sturgess, R. ;

Stern, N. ;

Sieberhagen, C. ;

Cross, T. ;

Camenzuli, A. ;

Davis, R. ;

Evans, J. ;

O'Grady, E. ;

Palmer, D. ;

Diaz-Nieto, R. ;

Fenwick, S. ;

Poston, G. ;

Malik, H. .

EJSO, 2019, 45 (09) :1660-1667

[5] Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors [J].

Andersen, Jesper B. ;

Spee, Bart ;

Blechacz, Boris R. ;

Avital, Itzhak ;

Komuta, Mina ;

Barbour, Andrew ;

Conner, Elizabeth A. ;

Gillen, Matthew C. ;

Roskams, Tania ;

Roberts, Lewis R. ;

Factor, Valentina M. ;

Thorgeirsson, Snorri S. .

GASTROENTEROLOGY, 2012, 142 (04) :1021-U552

[6] Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties [J].

Aoki, Shuichi ;

Mizuma, Masamichi ;

Takahashi, Yayoi ;

Haji, Yoichi ;

Okada, Ryo ;

Abe, Tomoya ;

Karasawa, Hideaki ;

Tamai, Keiichi ;

Okada, Takaho ;

Morikawa, Takanori ;

Hayashi, Hiroki ;

Nakagawa, Kei ;

Motoi, Fuyuhiko ;

Naitoh, Takeshi ;

Katayose, Yu ;

Unno, Michiaki .

BMC CANCER, 2016, 16

[7] Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma [J].

Arai, Yasuhito ;

Totoki, Yasushi ;

Hosoda, Fumie ;

Shirota, Tomoki ;

Hama, Natsuko ;

Nakamura, Hiromi ;

Ojima, Hidenori ;

Furuta, Koh ;

Shimada, Kazuaki ;

Okusaka, Takuji ;

Kosuge, Tomoo ;

Shibata, Tatsuhiro .

HEPATOLOGY, 2014, 59 (04) :1427-1434

[8] Cholangiocarcinoma 2020: the next horizon in mechanisms and management [J].

Banales, Jesus M. ;

Marin, Jose J. G. ;

Lamarca, Angela ;

Rodrigues, Pedro M. ;

Khan, Shahid A. ;

Roberts, Lewis R. ;

Cardinale, Vincenzo ;

Carpino, Guido ;

Andersen, Jesper B. ;

Braconi, Chiara ;

Calvisi, Diego F. ;

Perugorria, Maria J. ;

Fabris, Luca ;

Boulter, Luke ;

Macias, Rocio I. R. ;

Gaudio, Eugenio ;

Alvaro, Domenico ;

Gradilone, Sergio A. ;

Strazzabosco, Mario ;

Marzioni, Marco ;

Coulouarn, Cedric ;

Fouassier, Laura ;

Raggi, Chiara ;

Invernizzi, Pietro ;

Mertens, Joachim C. ;

Moncsek, Anja ;

Rizvi, Sumera ;

Heimbach, Julie ;

Koerkamp, Bas Groot ;

Bruix, Jordi ;

Forner, Alejandro ;

Bridgewater, John ;

Valle, Juan W. ;

Gores, Gregory J. .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2020, 17 (09) :557-588

[9] FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements [J].

Bekaii-Saab, Tanios S. ;

Valle, Juan W. ;

Van Cutsem, Eric ;

Rimassa, Lorenza ;

Furuse, Junji ;

Ioka, Tatsuya ;

Melisi, Davide ;

Macarulla, Teresa ;

Bridgewater, John ;

Wasan, Harpreet ;

Borad, Mitesh J. ;

Abou-Alfa, Ghassan K. ;

Jiang, Ping ;

Lihou, Christine F. ;

Zhen, Huiling ;

Asatiani, Ekaterine ;

Feliz, Luis ;

Vogel, Arndt .

FUTURE ONCOLOGY, 2020, 16 (30) :2385-2399

[10]

Borad MJ, 2020, J CLIN ONCOL, V38

← 1 2 3 4 5 6 7 8 9 10 →